Epic Test Code LAB162 Varicella-Zoster Antibody, IgG, Serum
Additional Codes
MML:VZPG
Reporting Name
Varicella-Zoster Ab, IgG, SUseful For
Determination of immune status of individuals to the varicella-zoster virus (VZV)
Documentation of previous infection with VZV in an individual without a previous record of immunization to VZV
Performing Laboratory
Mayo Clinic Laboratories in RochesterSpecimen Type
SerumSpecimen Required
Supplies: Sarstedt Aliquot Tube, 5 mL (T914)
Collection Container/Tube:
Preferred: Serum gel
Acceptable: Red top
Submission Container/Tube: Plastic vial
Specimen Volume: 0.5 mL
Collection Instructions: Centrifuge and aliquot serum into a plastic vial.
Specimen Minimum Volume
0.4 mL
Specimen Stability Information
Specimen Type | Temperature | Time | Special Container |
---|---|---|---|
Serum | Refrigerated (preferred) | 14 days | |
Frozen | 14 days |
Reference Values
Vaccinated: Positive (≥1.1 antibody index [AI])
Unvaccinated: Negative (≤0.8 AI)
Reference values apply to all ages.
Day(s) Performed
Monday through Saturday
CPT Code Information
86787
Clinical Information
Varicella-zoster virus (VZV), a herpes virus, causes 2 distinct exanthematous (rash-associated) diseases: chickenpox (varicella) and herpes zoster (shingles). Chickenpox is a highly contagious, though typically benign, disease, usually contracted during childhood. Chickenpox is characterized by a dermal vesiculopustular rash that develops in successive crops approximately 10 to 21 days following exposure.(1) Although primary infection with VZV results in immunity and protection from subsequent infection, VZV remains latent within sensory dorsal root ganglia and upon reactivation, manifests as herpes zoster or shingles. During reactivation, the virus migrates along neural pathways to the skin, producing a unilateral rash, usually limited to a single dermatome. Shingles is an extremely painful condition typically occurring in older nonimmune adults or those with waning immunity to VZV and in patients with impaired cellular immunity.(2)
Individuals at risk for severe complications following primary VZV infection include women who are pregnant, in whom the virus may spread through the placenta to the fetus, causing congenital disease in the infant. Additionally, immunosuppressed patients are at risk for developing severe VZV-related complications, which include cutaneous disseminated disease and visceral organ involvement.(2,3)
Serologic screening for IgG-class antibodies to VZV aids in identifying nonimmune individuals.
Interpretation
The reported antibody index (AI) value is for reference only. This is a qualitative test, and the numeric value of the AI is not indicative of the amount of antibody present. AI values above the manufacturer recommended cutoff for this assay indicate that specific antibodies were detected, suggesting prior exposure or vaccination.
Positive: AI value of 1.1 or higher:
The presence of detectable IgG-class antibodies indicates prior exposure to the varicella-zoster virus (VZV) through infection or immunization. Individuals testing positive are considered immune to varicella-zoster.
Equivocal: AI 0.9-1.0
Submit an additional specimen for testing in 10 to 14 days to demonstrate IgG seroconversion if recently vaccinated or if otherwise clinically indicated.
Negative: AI of 0.8 or lower
The absence of detectable IgG-class antibodies suggests no prior exposure to the VZV or the lack of a specific immune response to immunization.
Cautions
Immunoglobulin G-class antibodies to varicella-zoster virus may be present in serum specimens from individuals who have received blood products within the past several months but have not been immunized or experienced past infection with this virus.
Serum specimens drawn early during acute phase of infection may be negative for IgG-class antibodies to this virus.
Supportive Data
To evaluate the accuracy of the BioPlex Varicella-Zoster Virus (VZV) IgG multiplex flow immunoassay, 500 prospective serum samples were analyzed in a blinded fashion by the Diamedix VZV IgG enzyme immunoassay (EIA) (Diamedix) and the BioPlex VZV IgG assay. Samples with discordant results after initial testing were repeated by both assays during the same freeze/thaw cycle. Further discrepancies were evaluated by the SeraQuest VZV IgG EIA.(Quest International) The results are summarized in the Table below:
Table. Comparison between Bioplex and Diamedix Varicella-Zoster Virus (VZV) Assays
Diamedix VZV IgG EIA |
||||
BioPlex VZV IgG |
|
Positive |
Negative |
Equivocal |
Positive |
436 |
0 |
0 |
|
Negative |
18(a) |
22 |
4 |
|
Equivocal |
19 |
0 |
1 |
a. All 18 specimens tested positive by the SeraQuest VZV IgG EIA.
Sensitivity: 92.2% (436/473); 95% CI: 89.4%-94.3%
Specificity: 100.0 (22/22); 95% CI: 82.5%-100.0%
Overall percent agreement: 91.8% (459/500); 95% CI: 89.0%-93.9%
Report Available
Same day/1 to 3 daysSpecimen Retention Time
14 daysReject Due To
Gross hemolysis | Reject |
Gross lipemia | Reject |
Gross icterus | Reject |
Heat-inactivated specimen | Reject |
NY State Approved
YesMethod Name
Multiplex Flow Immunoassay (MFI)
Forms
If not ordering electronically, complete, print, and send 1 of the following forms with the specimen:
-General Request (T239)